Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Genetics

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 27 articles:
HTML format



Single Articles


    March 2022
  1. BOLGER JC, Donohoe CL, Lowery M, Reynolds JV, et al
    Advances in the curative management of oesophageal cancer.
    Br J Cancer. 2022;126:706-717.
    PubMed     Abstract available


    January 2022
  2. LAL N, Chan DKH, Ng ME, Vermeulen L, et al
    Primary tumour immune response and lymph node yields in colon cancer.
    Br J Cancer. 2022 Jan 18. pii: 10.1038/s41416-022-01700.
    PubMed     Abstract available


  3. SUN J, Yan C, Xu D, Zhang Z, et al
    Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy.
    Br J Cancer. 2022 Jan 11. pii: 10.1038/s41416-021-01692.
    PubMed     Abstract available


    December 2021
  4. ZHANG X, Li X, He Y, Law PJ, et al
    Phenome-wide association study (PheWAS) of colorectal cancer risk SNP effects on health outcomes in UK Biobank.
    Br J Cancer. 2021 Dec 15. pii: 10.1038/s41416-021-01655.
    PubMed     Abstract available


    November 2021
  5. ROMUALDO CARDOSO S, Gillespie A, Haider S, Fletcher O, et al
    Functional annotation of breast cancer risk loci: current progress and future directions.
    Br J Cancer. 2021 Nov 5. pii: 10.1038/s41416-021-01612.
    PubMed     Abstract available


  6. HAKOZAKI K, Tanaka N, Takamatsu K, Takahashi R, et al
    Landscape of prognostic signatures and immunogenomics of the AXL/GAS6 axis in renal cell carcinoma.
    Br J Cancer. 2021;125:1533-1543.
    PubMed     Abstract available


    September 2021
  7. CHEN D, Bao X, Zhang R, Ding Y, et al
    Depiction of the genomic and genetic landscape identifies CCL5 as a protective factor in colorectal neuroendocrine carcinoma.
    Br J Cancer. 2021;125:994-1002.
    PubMed     Abstract available


  8. CRISPIN-ORTUZAR M, Sala E
    Precision radiogenomics: fusion biopsies to target tumour habitats in vivo.
    Br J Cancer. 2021;125:778-779.
    PubMed     Abstract available


    August 2021
  9. GEVAERT O
    Meta-learning reduces the amount of data needed to build AI models in oncology.
    Br J Cancer. 2021;125:309-310.
    PubMed     Abstract available


    July 2021
  10. LEI JT, Zhang B
    Proteogenomics drives therapeutic hypothesis generation for precision oncology.
    Br J Cancer. 2021;125:1-3.
    PubMed     Abstract available


    June 2021
  11. LEE KH, Chen WS, Jiang JK, Yang SH, et al
    The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon.
    Br J Cancer. 2021 Jun 29. pii: 10.1038/s41416-021-01470.
    PubMed     Abstract available


    May 2021
  12. SINGH G, Manjila S, Sakla N, True A, et al
    Radiomics and radiogenomics in gliomas: a contemporary update.
    Br J Cancer. 2021 May 6. pii: 10.1038/s41416-021-01387.
    PubMed     Abstract available


    February 2021
  13. ROSENTHAL R, Swanton C, McGranahan N
    Understanding the impact of immune-mediated selection on lung cancer evolution.
    Br J Cancer. 2021 Feb 24. pii: 10.1038/s41416-020-01232.
    PubMed     Abstract available


    January 2021
  14. BARROW TM, Nakjang S, Lafta F, Bilotkach K, et al
    Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia.
    Br J Cancer. 2021;124:474-483.
    PubMed     Abstract available


    October 2020
  15. CHA PH, Hwang JH, Kwak DK, Koh E, et al
    APC loss induces Warburg effect via increased PKM2 transcription in colorectal cancer.
    Br J Cancer. 2020 Oct 19. pii: 10.1038/s41416-020-01118.
    PubMed     Abstract available


    July 2020
  16. HORNIGOLD N, Dunn KR, Craven RA, Zougman A, et al
    Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion.
    Br J Cancer. 2020;123:137-147.
    PubMed     Abstract available


    May 2020
  17. FORD CE, Werner B, Hacker NF, Warton K, et al
    The untapped potential of ascites in ovarian cancer research and treatment.
    Br J Cancer. 2020 May 8. pii: 10.1038/s41416-020-0875.
    PubMed     Abstract available


    March 2020
  18. LUCA BA, Moulton V, Ellis C, Edwards DR, et al
    A novel stratification framework for predicting outcome in patients with prostate cancer.
    Br J Cancer. 2020 Mar 20. pii: 10.1038/s41416-020-0799.
    PubMed     Abstract available


  19. POWLEY IR, Patel M, Miles G, Pringle H, et al
    Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery.
    Br J Cancer. 2020;122:735-744.
    PubMed     Abstract available


    February 2020
  20. NIEGISCH G
    Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
    Br J Cancer. 2020;122:453-454.
    PubMed     Abstract available


  21. VISSIO E, Metovic J, Osella-Abate S, Bertero L, et al
    Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling.
    Br J Cancer. 2020;122:382-387.
    PubMed     Abstract available


    January 2020
  22. WHITWELL HJ, Worthington J, Blyuss O, Gentry-Maharaj A, et al
    Improved early detection of ovarian cancer using longitudinal multimarker models.
    Br J Cancer. 2020 Jan 15. pii: 10.1038/s41416-019-0718.
    PubMed     Abstract available


    August 2019
  23. KORPHAISARN K, Morris V, Davis JS, Overman MJ, et al
    Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma.
    Br J Cancer. 2019 Aug 13. pii: 10.1038/s41416-019-0548.
    PubMed     Abstract available


    July 2019
  24. BRAR G, Blais EM, Joseph Bender R, Brody JR, et al
    Multi-omic molecular comparison of primary versus metastatic pancreatic tumours.
    Br J Cancer. 2019;121:264-270.
    PubMed     Abstract available


  25. WILLEMSEN AECAB, Krausz S, Ligtenberg MJL, Grunberg K, et al
    Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations.
    Br J Cancer. 2019;121:34-36.
    PubMed     Abstract available


    April 2019
  26. IACHETTA F, Bonelli C, Romagnani A, Zamponi R, et al
    The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study.
    Br J Cancer. 2019;120:834-839.
    PubMed     Abstract available


    March 2019
  27. GIOVANNINI C, Salzano AM, Baglioni M, Vitale M, et al
    Brivanib in combination with Notch3 silencing shows potent activity in tumour models.
    Br J Cancer. 2019;120:601-611.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Genetics is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: